X4 Pharmaceuticals (NASDAQ:XFOR) President John Volpone Sells 24,576 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) President John Volpone sold 24,576 shares of X4 Pharmaceuticals stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $109,117.44. Following the completion of the sale, the president owned 265,305 shares in the company, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $4.29 on Friday. The firm has a market capitalization of $425.35 million, a price-to-earnings ratio of -3.57 and a beta of 0.37. The stock has a fifty day moving average of $4.04 and a 200 day moving average of $3.96. X4 Pharmaceuticals, Inc. has a 52 week low of $2.45 and a 52 week high of $4.83. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. As a group, research analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Empery Asset Management LP purchased a new stake in X4 Pharmaceuticals in the fourth quarter worth about $35,804,000. Bain Capital Life Sciences Investors LLC lifted its holdings in shares of X4 Pharmaceuticals by 227.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after purchasing an additional 5,530,866 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in shares of X4 Pharmaceuticals by 6.7% during the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after purchasing an additional 423,196 shares during the last quarter. Kalehua Capital Management LLC bought a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth approximately $14,891,000. Finally, Braidwell LP purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth approximately $13,476,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on XFOR shares. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target for the company. Leerink Partners started coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings lowered X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.